Merck & Co's MK-677 fails in Alzheimer's Phase II
This article was originally published in Scrip
Executive Summary
Merck & Co's investigational compound, MK-677 (ibutamoren mesylate), a potent inducer of insulin-like growth factor–1 (IGF-1), has failed to reduce symptoms of Alzheimer's disease, according to a Phase II study published in the journal Neurology.